IAG & McMaster University Partner to Advance GBM Drug Development

IAG & McMaster University Partner to Advance GBM Drug Development

IAG Partners with McMaster University Advance Multi-Omics-Based Machine Learning Models for Glioblastoma Drug Development

IAG, Image Analysis Group has partnered with the Singh Lab, led by Dr Sheila Singh to advance prognostication models for glioblastoma (GBM) drug development.

The partners will pursue an entirely novel approach using radiomics (advanced quantitative image analysis), proteomics (large-scale study of proteins) and transcriptomics (DNA microarray assessment of gene expression) to evaluate the microstructural and functional characteristics of glioblastomas.

To accelerate drug development and help efficient patient stratification, it is critical to assess the tumours’ aggressive potential. The partners will be building Machine Learning AI -driven models for tumour stratification and early assessment of drug efficacy. Thus, allowing clinical practitioners, biotech and pharma companies focused on GBM drug development to benefit from the latest innovations.

With a novel multi-omics approach we plan to discover new predictive biomarkers of recurrence patterns of the most common adult primary brain tumour, GBM. There is a whole spectrum of biological factors that contribute to how these cancers behave, such as the genes expressed, proteins secreted, and microstructural changes rendered. Studying these individually and incorporating them together allows us to classify these cancers. Thus, permitting to treat each patient based on the unique characteristics of their cancer and the pattern of their recurrence.”  Dr Singh commented.

This is a step towards precision medicine. ”, says Faiq Shaikh, M.D., IAG’s Head of Oncology & Radiomics. “While proteomics, genomics and radiomics have been leveraged individually in many of our studies, this is the first time a fully integrated multi-omics approach will be developed to support the understanding and management of a malignant disease,” commented Dr. Diana Dupont-Roettger, the Chief Scientific Alliance Officer, IAG.


Click here to read the full press release and expert view on the use of advanced imaging and AI in neuro-oncology drug development.

About Image Analysis Group (IAG)

IAG, Image Analysis Group is a unique partner to life sciences companies. IAG leverages expertise in medical imaging and the power of Dynamika™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner.  IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, radiological expertise via risk-sharing financing and partnering models.

Learn more:  wp1.ia-grp.com

Reach out: imaging.experts@ia-grp.com

Follow the Company: Linkedin